Gainers

• Cyclerion Therapeutics (NASDAQ:CYCN) stock moved upwards by 140.0% to $3.72 during Wednesday's pre-market session. The market value of their outstanding shares is at $5.8 million.
• bioAffinity Technologies (NASDAQ:BIAF) stock rose 13.83% to $4.36. The market value of their outstanding shares is at $17.2 million.
• Ascentage Pharma Group (NASDAQ:AAPG) stock rose 9.59% to $26.16. The market value of their outstanding shares is at $2.2 billion.
• Sonoma Pharmaceuticals (NASDAQ:SNOA) stock increased by 9.12% to $2.32. The market value of their outstanding shares is at $3.6 million.
• Kala Bio (NASDAQ:KALA) shares increased by 8.72% to $0.19. The market value of their outstanding shares is at $157.7 million.
• Axe Compute (NASDAQ:AGPU) shares increased by 8.02% to $1.75. The company's market cap stands at $5.4 million. The company's, Q4 earnings came out yesterday.

Losers

• ORIC Pharmaceuticals (NASDAQ:ORIC) shares fell 21.5% to $9.95 during Wednesday's pre-market session. The company's market cap stands at $1.4 billion.
• Passage Bio (NASDAQ:PASG) stock declined by 20.77% to $6.22. The company's market cap stands at $24.9 million.
• IO Biotech (NASDAQ:IOBT) stock declined by 19.09% to $0.05. The market value of their outstanding shares is at $4.2 million.
• BioAtla (NASDAQ:BCAB) shares decreased by 16.15% to $0.14. The market value of their outstanding shares is at $13.3 million. The company's, Q4 earnings came out yesterday.
• Dogwood Therapeutics (NASDAQ:DWTX) shares fell 14.7% to $1.8. The company's market cap stands at $70.4 million.
• Virax Biolabs Group (NASDAQ:VRAX) stock decreased by 12.28% to $0.19. The market value of their outstanding shares is at $1.6 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.